Abstract
The aging population is the fastest growing segment of our population. Over the last century, the average life expectancy has increased by 25 years. The incidence of ovarian carcinoma, seen primarily in postmenopausal women, is, therefore, expected to increase. The current standard treatment of ovarian cancer has been determined on the basis of prospective, randomised clinical trials carried out by cooperative groups. Sixty-one percent of new cancer cases occur in women >65 years of age. Despite this fact, enrolment in clinical trials has been exceedingly low. In turn, this causes suboptimal treatment for a very fatal disease. The aetiology of this is multifactorial, and strategies for improvement are lacking. Elderly patients may be barred from participation based on physician biases alone. Elderly patients may have limited access to academic centres where clinical trials are conducted or be excluded on the basis of unrealistic inclusion criteria. As physicians, it is our duty to understand the elderly patient and the comorbidities in this age group that may influence the tolerability and toxicity of conventional therapies. Therefore, it is imperative that we make a conscious effort to examine ways in which we may improve enrolment of elderly women with ovarian cancer in clinical trials.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
NCI. National Cancer Institute, Surveillance Research Program, Cancer Statistics Branch. In: SEER Public-Use Database, (1969–2000) 2003 ed. Based on the November 2002 submission. Issued [online]. Available from URL: http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_Fact-s_Figures_2003.asp [Accessed 2004 Sep 29]
Mirhashemi R, Nieves-Neira W, Averette HE. Gynecologic malignancies in older women. Oncology (Huntingt) 2001; 15(5): 580–6
Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341(27): 2061–7
Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003; 21(7): 1383–9
Talarico L, Chen G, Padzur R. Elderly patients in trials for drug cancer registration: a 7-year experience by the Food and Drug Administration (FDA) [abstract no. 2928]. 39th Annual Meeting of the American Society of Clinical Oncology; 2003 May 31–Jun 3; Chicago (IL). Proc Am Soc Clin Oncol 2003; 22: 728
DeMichele A, Putt M, Zhang Y, et al. Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma: evidence from a tertiary care cohort of chemotherapy-eligible patients. Cancer 2003; 97(9): 2150–9
Villella JA, Chaudhry T, Pearl ML, et al. Comparison of tolerance of combination carboplatin and paclitaxel chemotherapy by age in women with ovarian cancer. Gynecol Oncol 2002; 86(3): 316–22
Pearl ML, McCauley DL, Thompson J, et al. A randomized controlled trial of early oral analgesia in gynecologic oncology patients undergoing intra-abdominal surgery. Obstet Gynecol 2002; 99 (5 Pt 1): 704–8
Pearl ML, Valea FA, Fischer M, et al. A randomized controlled trial of postoperative nasogastric tube decompression in gynecologic oncology patients undergoing intra-abdominal surgery. Obstet Gynecol 1996; 88(3): 399–402
Pearl ML, Valea FA, Fischer M, et al. A randomized controlled trial of early postoperative feeding in gynecologic oncology patients undergoing intra-abdominal surgery. Obstet Gynecol 1998; 92(1): 94–7
Sundararajan V, Hershman D, Grann VR, et al. Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol 2002; 20(1): 173–8
Hershman D, Jacobson JS, McBride R, et al. Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer. Gynecol Oncol 2004; 94(2): 540–9
Kitler ME. Clinical trials and clinical practice in the elderly: a focus on hypertension. Drugs Aging 1992; 2(2): 86–94
Abernathy D. Research challenges, new drug development, preclinical and clinical trials in the aging population. Drug Saf 1990; 5Suppl. 1: 71–4
Belinson JL, Jarrell MA, McClure M, et al. Serum albumin: its relationship to marrow and renal toxicity from platinum-based combination chemotherapy. Gynecol Oncol 1990; 37(1): 93–5
Ceccaroni M, D’Agostino G, Ferrandina G, et al. Gynecological malignancies in elderly patients: is age 70 a limit to standard-dose chemotherapy? An Italian retrospective toxicity multicentric study. Gynecol Oncol 2002; 85(3): 445–50
Thigpen T, Brady MF, Omura GA, et al. Age as a prognostic factor in ovarian carcinoma: the Gynecologic Oncology Group experience. Cancer 1993; 71(2 Suppl.): 606–14
Moore DH, Kauderer JT, Bell J, et al. An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 94(2): 368–74
van Eijken M, Tsang S, Wensing M, et al. Interventions to improve medication compliance in older patients living in the community: a systematic review of the literature. Drugs Aging 2003; 20(3): 229–40
German PS, Klein LE, McPhee SJ, et al. Knowledge of and compliance with drug regimens in the elderly. J Am Geriatr Soc 1982; 30(9): 568–71
Acknowledgements
The authors have provided no information on sources of funding or on conflicts of interest directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Villella, J., Chalas, E. Optimising Treatment of Elderly Patients with Ovarian Cancer. Drugs Aging 22, 95–100 (2005). https://doi.org/10.2165/00002512-200522020-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002512-200522020-00001